{
  "id": "451b8bb148a29797",
  "title": "STAT+: Alnylam charts ambitious five-year plan as sales of key drug miss expectations",
  "description": "Gene-silencing company Alnylam charts ambitious five-year plan as sales of key drug miss expectations.",
  "content": "Gene-silencing company Alnylam charts ambitious five-year plan as sales of key drug miss expectations.",
  "source": "STAT",
  "source_url": "https://www.statnews.com/2026/01/11/alnylam-five-year-plan-amvuttra-investors-jpm-2026/?utm_campaign=rss",
  "published_at": "2026-01-11T22:00:00+00:00",
  "fetched_at": "2026-01-12T00:24:39.879979+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "drug"
  ],
  "location": null,
  "raw_data": {
    "title": "STAT+: Alnylam charts ambitious five-year plan as sales of key drug miss expectations",
    "description": "Gene-silencing company Alnylam charts ambitious five-year plan as sales of key drug miss expectations.",
    "url": "https://www.statnews.com/2026/01/11/alnylam-five-year-plan-amvuttra-investors-jpm-2026/?utm_campaign=rss",
    "published": "2026-01-11T22:00:00+00:00",
    "source": "STAT"
  }
}